Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Community Pharmacy Services | 1 | 2016 | 5 | 0.600 |
Why?
|
Community Health Planning | 1 | 2016 | 21 | 0.590 |
Why?
|
Professional Role | 1 | 2016 | 41 | 0.580 |
Why?
|
Precision Medicine | 3 | 2021 | 394 | 0.550 |
Why?
|
Colorectal Neoplasms | 3 | 2012 | 924 | 0.510 |
Why?
|
Genetic Heterogeneity | 1 | 2014 | 62 | 0.490 |
Why?
|
Patient Care Team | 1 | 2016 | 280 | 0.490 |
Why?
|
Pharmacogenetics | 1 | 2016 | 434 | 0.440 |
Why?
|
DNA Glycosylases | 1 | 2012 | 24 | 0.440 |
Why?
|
Adenomatous Polyposis Coli Protein | 1 | 2012 | 39 | 0.430 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2012 | 39 | 0.430 |
Why?
|
Haplotypes | 1 | 2014 | 642 | 0.420 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2012 | 378 | 0.410 |
Why?
|
Antineoplastic Agents | 11 | 2021 | 2351 | 0.400 |
Why?
|
Neoplasms | 9 | 2023 | 2889 | 0.400 |
Why?
|
Surveys and Questionnaires | 3 | 2016 | 2495 | 0.390 |
Why?
|
Adenoma | 1 | 2012 | 234 | 0.370 |
Why?
|
Skin Neoplasms | 7 | 2013 | 541 | 0.360 |
Why?
|
Breast Neoplasms | 19 | 2013 | 2881 | 0.310 |
Why?
|
Biomarkers, Tumor | 2 | 2021 | 1461 | 0.290 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2006 | 155 | 0.270 |
Why?
|
Humans | 75 | 2023 | 86281 | 0.250 |
Why?
|
Mutation | 3 | 2023 | 3952 | 0.250 |
Why?
|
Aged | 41 | 2021 | 18353 | 0.230 |
Why?
|
Middle Aged | 47 | 2021 | 24957 | 0.220 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2005 | 407 | 0.220 |
Why?
|
Female | 53 | 2021 | 44405 | 0.220 |
Why?
|
Postmenopause | 7 | 2013 | 98 | 0.210 |
Why?
|
Dietary Fats | 4 | 2009 | 134 | 0.210 |
Why?
|
Prostatic Neoplasms | 6 | 2016 | 1708 | 0.210 |
Why?
|
ErbB Receptors | 1 | 2005 | 485 | 0.210 |
Why?
|
Sickle Cell Trait | 1 | 2021 | 21 | 0.200 |
Why?
|
Outpatients | 1 | 2021 | 94 | 0.200 |
Why?
|
Viral Load | 1 | 2021 | 148 | 0.200 |
Why?
|
Biological Specimen Banks | 1 | 2021 | 64 | 0.190 |
Why?
|
Venous Thromboembolism | 1 | 2023 | 151 | 0.190 |
Why?
|
Protein Kinase Inhibitors | 1 | 2005 | 589 | 0.190 |
Why?
|
Thrombosis | 1 | 2023 | 296 | 0.190 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2021 | 877 | 0.190 |
Why?
|
Genital Neoplasms, Female | 1 | 2021 | 107 | 0.190 |
Why?
|
Antibodies, Viral | 1 | 2021 | 293 | 0.180 |
Why?
|
Patient Care Planning | 2 | 2021 | 81 | 0.180 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2015 | 1305 | 0.170 |
Why?
|
Antibodies, Monoclonal | 2 | 2005 | 1376 | 0.170 |
Why?
|
Carcinoma, Basal Cell | 3 | 2004 | 54 | 0.170 |
Why?
|
Male | 34 | 2021 | 40860 | 0.160 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 455 | 0.160 |
Why?
|
Isotretinoin | 1 | 2017 | 23 | 0.160 |
Why?
|
Ovarian Neoplasms | 5 | 2007 | 738 | 0.160 |
Why?
|
Coronary Artery Disease | 2 | 2012 | 347 | 0.150 |
Why?
|
Patient Education as Topic | 2 | 2015 | 351 | 0.150 |
Why?
|
Molecular Biology | 1 | 1997 | 89 | 0.150 |
Why?
|
Genetic Testing | 2 | 2021 | 535 | 0.150 |
Why?
|
Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 52 | 0.150 |
Why?
|
Proportional Hazards Models | 4 | 2016 | 857 | 0.150 |
Why?
|
Dermatologic Agents | 1 | 2017 | 71 | 0.140 |
Why?
|
Carcinoma | 3 | 1995 | 434 | 0.140 |
Why?
|
Terminology as Topic | 1 | 1997 | 217 | 0.140 |
Why?
|
BRCA2 Protein | 1 | 2016 | 157 | 0.140 |
Why?
|
Aftercare | 1 | 1996 | 84 | 0.130 |
Why?
|
BRCA1 Protein | 1 | 2016 | 199 | 0.130 |
Why?
|
Pleural Effusion, Malignant | 1 | 1995 | 15 | 0.130 |
Why?
|
Cisplatin | 2 | 1990 | 612 | 0.130 |
Why?
|
Melanoma | 2 | 2012 | 454 | 0.130 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2017 | 1075 | 0.130 |
Why?
|
Pleura | 1 | 1995 | 30 | 0.130 |
Why?
|
Prospective Studies | 10 | 2023 | 4194 | 0.130 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 252 | 0.130 |
Why?
|
Germ-Line Mutation | 1 | 2016 | 329 | 0.120 |
Why?
|
Self Care | 1 | 2015 | 164 | 0.120 |
Why?
|
Dysgerminoma | 1 | 1993 | 7 | 0.120 |
Why?
|
Health Promotion | 1 | 2015 | 160 | 0.120 |
Why?
|
Fallopian Tube Neoplasms | 1 | 1993 | 35 | 0.120 |
Why?
|
Patient-Centered Care | 1 | 2015 | 202 | 0.110 |
Why?
|
Quality Indicators, Health Care | 2 | 2012 | 144 | 0.110 |
Why?
|
Malpractice | 1 | 1993 | 57 | 0.110 |
Why?
|
Risk | 3 | 2011 | 673 | 0.110 |
Why?
|
Risk Factors | 7 | 2023 | 5397 | 0.110 |
Why?
|
Mass Screening | 1 | 1996 | 615 | 0.100 |
Why?
|
Adenocarcinoma | 9 | 1994 | 1160 | 0.100 |
Why?
|
Anthropometry | 1 | 2011 | 74 | 0.100 |
Why?
|
Breast | 3 | 2010 | 286 | 0.100 |
Why?
|
Adult | 25 | 2021 | 25577 | 0.100 |
Why?
|
Demography | 1 | 2011 | 177 | 0.100 |
Why?
|
Lip Neoplasms | 1 | 1990 | 8 | 0.100 |
Why?
|
Cardiopulmonary Bypass | 1 | 2012 | 148 | 0.100 |
Why?
|
Total Quality Management | 1 | 2011 | 34 | 0.100 |
Why?
|
Head and Neck Neoplasms | 2 | 2017 | 1051 | 0.100 |
Why?
|
Electronic Health Records | 2 | 2012 | 319 | 0.100 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 362 | 0.100 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2004 | 100 | 0.100 |
Why?
|
Urinary Bladder Neoplasms | 2 | 1993 | 376 | 0.100 |
Why?
|
Time Factors | 6 | 2013 | 5198 | 0.100 |
Why?
|
Amygdalin | 2 | 1980 | 3 | 0.090 |
Why?
|
Linoleic Acid | 1 | 2009 | 5 | 0.090 |
Why?
|
Decision Support Systems, Clinical | 1 | 2011 | 103 | 0.090 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2010 | 85 | 0.090 |
Why?
|
Arachidonic Acid | 1 | 2009 | 63 | 0.090 |
Why?
|
Eicosapentaenoic Acid | 1 | 2009 | 19 | 0.090 |
Why?
|
Coronary Artery Bypass | 1 | 2012 | 228 | 0.090 |
Why?
|
Sensitivity and Specificity | 3 | 2007 | 1987 | 0.090 |
Why?
|
Docosahexaenoic Acids | 1 | 2009 | 31 | 0.090 |
Why?
|
Endothelium, Vascular | 1 | 2012 | 435 | 0.090 |
Why?
|
Anticarcinogenic Agents | 1 | 2009 | 70 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2007 | 2434 | 0.090 |
Why?
|
United States | 5 | 2017 | 6637 | 0.090 |
Why?
|
Practice Patterns, Physicians' | 2 | 2012 | 578 | 0.080 |
Why?
|
Quality Improvement | 1 | 2012 | 423 | 0.080 |
Why?
|
Pancreatic Neoplasms | 2 | 2007 | 645 | 0.080 |
Why?
|
CA-125 Antigen | 1 | 2007 | 22 | 0.080 |
Why?
|
Drug Evaluation | 13 | 1989 | 141 | 0.080 |
Why?
|
alpha-Fetoproteins | 1 | 2007 | 45 | 0.080 |
Why?
|
Neoplasms, Radiation-Induced | 3 | 2001 | 109 | 0.080 |
Why?
|
Repressor Proteins | 1 | 2010 | 403 | 0.070 |
Why?
|
DNA-Binding Proteins | 2 | 2010 | 1208 | 0.070 |
Why?
|
Odds Ratio | 3 | 2021 | 677 | 0.070 |
Why?
|
Proto-Oncogene Proteins | 1 | 2010 | 645 | 0.070 |
Why?
|
Teniposide | 2 | 1986 | 6 | 0.070 |
Why?
|
Podophyllotoxin | 2 | 1986 | 10 | 0.070 |
Why?
|
Internal Medicine | 2 | 2011 | 347 | 0.070 |
Why?
|
Urologic Neoplasms | 2 | 1989 | 77 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 2009 | 532 | 0.070 |
Why?
|
Women's Health | 3 | 2013 | 100 | 0.070 |
Why?
|
Follow-Up Studies | 7 | 2017 | 3616 | 0.070 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2001 | 111 | 0.070 |
Why?
|
Work Schedule Tolerance | 1 | 2005 | 36 | 0.070 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2014 | 2350 | 0.070 |
Why?
|
Nuclear Proteins | 1 | 2010 | 694 | 0.070 |
Why?
|
Neoplasm Metastasis | 10 | 2007 | 1056 | 0.070 |
Why?
|
Neoplasm Staging | 7 | 2017 | 1932 | 0.070 |
Why?
|
Transcription, Genetic | 1 | 2010 | 1135 | 0.070 |
Why?
|
Carcinoma, Transitional Cell | 2 | 1989 | 164 | 0.070 |
Why?
|
Biomarkers | 1 | 2012 | 1709 | 0.070 |
Why?
|
Transcription Factors | 2 | 2010 | 1555 | 0.070 |
Why?
|
Prostate-Specific Antigen | 1 | 2007 | 346 | 0.070 |
Why?
|
Endometrial Neoplasms | 1 | 2007 | 191 | 0.060 |
Why?
|
Feeding Behavior | 1 | 2007 | 324 | 0.060 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2005 | 93 | 0.060 |
Why?
|
Neoplasm Invasiveness | 3 | 2009 | 551 | 0.060 |
Why?
|
Aged, 80 and over | 6 | 2017 | 6481 | 0.060 |
Why?
|
Liver Neoplasms | 3 | 2007 | 731 | 0.060 |
Why?
|
Progesterone Congeners | 1 | 2003 | 4 | 0.060 |
Why?
|
Factor V | 1 | 2023 | 10 | 0.060 |
Why?
|
Prothrombin | 1 | 2023 | 18 | 0.060 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2003 | 16 | 0.060 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2003 | 21 | 0.060 |
Why?
|
Estrogen Replacement Therapy | 1 | 2003 | 45 | 0.060 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2007 | 380 | 0.060 |
Why?
|
Diethylstilbestrol | 2 | 1985 | 119 | 0.060 |
Why?
|
Predictive Value of Tests | 1 | 2007 | 1671 | 0.060 |
Why?
|
Treatment Outcome | 3 | 2012 | 7949 | 0.050 |
Why?
|
Reminder Systems | 2 | 2012 | 16 | 0.050 |
Why?
|
Preexisting Condition Coverage | 1 | 2021 | 3 | 0.050 |
Why?
|
Hemangiosarcoma | 1 | 2001 | 17 | 0.050 |
Why?
|
Hypoglycemia | 1 | 1982 | 106 | 0.050 |
Why?
|
Menogaril | 1 | 2001 | 3 | 0.050 |
Why?
|
Vascular Neoplasms | 1 | 2001 | 19 | 0.050 |
Why?
|
Population | 1 | 2021 | 35 | 0.050 |
Why?
|
Prognosis | 5 | 2017 | 3669 | 0.050 |
Why?
|
Thiadiazoles | 2 | 1994 | 12 | 0.050 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2001 | 40 | 0.050 |
Why?
|
United Kingdom | 1 | 2021 | 164 | 0.050 |
Why?
|
Neutropenia | 1 | 2021 | 215 | 0.050 |
Why?
|
Rectal Neoplasms | 3 | 1987 | 114 | 0.050 |
Why?
|
Thrombocytopenia | 1 | 2021 | 183 | 0.050 |
Why?
|
Adenoma, Islet Cell | 1 | 1979 | 28 | 0.050 |
Why?
|
Polycomb Repressive Complex 2 | 2 | 2010 | 30 | 0.050 |
Why?
|
Enhancer of Zeste Homolog 2 Protein | 2 | 2010 | 35 | 0.050 |
Why?
|
Mammography | 1 | 2003 | 460 | 0.050 |
Why?
|
Paraneoplastic Syndromes | 1 | 1979 | 16 | 0.050 |
Why?
|
Glioblastoma | 2 | 1996 | 254 | 0.050 |
Why?
|
Semustine | 1 | 1979 | 2 | 0.050 |
Why?
|
Survival Analysis | 3 | 2016 | 1536 | 0.050 |
Why?
|
Nitrosourea Compounds | 1 | 1979 | 9 | 0.050 |
Why?
|
DNA Mutational Analysis | 1 | 2021 | 526 | 0.050 |
Why?
|
Central Nervous System Diseases | 1 | 1979 | 52 | 0.040 |
Why?
|
Diabetes Complications | 1 | 2021 | 206 | 0.040 |
Why?
|
Glucagon | 1 | 1979 | 111 | 0.040 |
Why?
|
Neoplasm Seeding | 1 | 1979 | 16 | 0.040 |
Why?
|
Incidence | 3 | 2012 | 1568 | 0.040 |
Why?
|
Cost-Benefit Analysis | 2 | 1996 | 450 | 0.040 |
Why?
|
Nipples | 1 | 1979 | 35 | 0.040 |
Why?
|
Molecular Targeted Therapy | 1 | 2021 | 266 | 0.040 |
Why?
|
Methylation | 2 | 2010 | 251 | 0.040 |
Why?
|
Combined Modality Therapy | 6 | 1996 | 1680 | 0.040 |
Why?
|
Heat-Shock Proteins | 1 | 1999 | 178 | 0.040 |
Why?
|
Down-Regulation | 2 | 2010 | 504 | 0.040 |
Why?
|
Histones | 2 | 2010 | 309 | 0.040 |
Why?
|
Animals | 4 | 2014 | 26518 | 0.040 |
Why?
|
Retrospective Studies | 3 | 2021 | 8431 | 0.040 |
Why?
|
Physical Examination | 3 | 1996 | 149 | 0.040 |
Why?
|
Carcinoma 256, Walker | 2 | 1979 | 4 | 0.040 |
Why?
|
Colonic Neoplasms | 3 | 1987 | 554 | 0.040 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 1978 | 111 | 0.040 |
Why?
|
Time | 1 | 1977 | 77 | 0.040 |
Why?
|
Leukemia, Erythroblastic, Acute | 1 | 1977 | 29 | 0.040 |
Why?
|
Paclitaxel | 1 | 1998 | 460 | 0.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 1998 | 276 | 0.040 |
Why?
|
Mesothelioma | 2 | 1995 | 309 | 0.040 |
Why?
|
Brain Neoplasms | 3 | 1996 | 763 | 0.040 |
Why?
|
Benzoquinones | 2 | 1987 | 27 | 0.040 |
Why?
|
Cerebellar Neoplasms | 2 | 1987 | 36 | 0.040 |
Why?
|
Medical History Taking | 1 | 1996 | 80 | 0.040 |
Why?
|
Internship and Residency | 1 | 2005 | 1001 | 0.040 |
Why?
|
Transitional Care | 1 | 2015 | 18 | 0.030 |
Why?
|
Neoplasm Grading | 1 | 2016 | 356 | 0.030 |
Why?
|
Gene Expression | 1 | 1999 | 1281 | 0.030 |
Why?
|
Thoracotomy | 1 | 1995 | 58 | 0.030 |
Why?
|
Multiple Myeloma | 1 | 1998 | 307 | 0.030 |
Why?
|
Health Care Costs | 1 | 1996 | 237 | 0.030 |
Why?
|
Survival Rate | 2 | 1996 | 1856 | 0.030 |
Why?
|
Uterine Neoplasms | 1 | 1978 | 225 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2010 | 2421 | 0.030 |
Why?
|
Drainage | 1 | 1995 | 157 | 0.030 |
Why?
|
Ambulatory Care | 1 | 2015 | 180 | 0.030 |
Why?
|
New Jersey | 1 | 1993 | 4 | 0.030 |
Why?
|
Survivors | 1 | 2015 | 225 | 0.030 |
Why?
|
Sunlight | 1 | 2013 | 26 | 0.030 |
Why?
|
Continuity of Patient Care | 1 | 2015 | 169 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2016 | 853 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2007 | 1958 | 0.030 |
Why?
|
Double-Blind Method | 1 | 2017 | 1822 | 0.030 |
Why?
|
Radioisotope Teletherapy | 1 | 1992 | 4 | 0.030 |
Why?
|
Mastectomy, Modified Radical | 1 | 1992 | 6 | 0.030 |
Why?
|
Cobalt Radioisotopes | 1 | 1992 | 19 | 0.030 |
Why?
|
Reimbursement, Incentive | 1 | 2012 | 37 | 0.030 |
Why?
|
Zoxazolamine | 1 | 1972 | 2 | 0.030 |
Why?
|
Hexobarbital | 1 | 1972 | 2 | 0.030 |
Why?
|
Risk Assessment | 2 | 2012 | 2253 | 0.030 |
Why?
|
Creatine Kinase, MB Form | 1 | 2012 | 6 | 0.030 |
Why?
|
Microsomes, Liver | 1 | 1972 | 49 | 0.030 |
Why?
|
Patient Compliance | 1 | 1993 | 226 | 0.030 |
Why?
|
Myocardium | 2 | 2012 | 528 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2016 | 1801 | 0.030 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2012 | 80 | 0.030 |
Why?
|
Creatine Kinase | 1 | 2012 | 52 | 0.030 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2012 | 56 | 0.030 |
Why?
|
Phosphoric Acids | 1 | 1971 | 5 | 0.030 |
Why?
|
Feedback | 1 | 2012 | 132 | 0.030 |
Why?
|
Age Factors | 1 | 2016 | 1842 | 0.030 |
Why?
|
Recurrence | 1 | 1995 | 1137 | 0.030 |
Why?
|
Troponin I | 1 | 2012 | 26 | 0.030 |
Why?
|
Insecticides | 1 | 1971 | 27 | 0.030 |
Why?
|
Lymphatic Metastasis | 1 | 1993 | 480 | 0.030 |
Why?
|
Complement Activation | 1 | 2012 | 81 | 0.030 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2012 | 152 | 0.030 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 231 | 0.020 |
Why?
|
Cyclophosphamide | 4 | 1992 | 299 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2012 | 160 | 0.020 |
Why?
|
Vitamin D | 1 | 2013 | 261 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 376 | 0.020 |
Why?
|
Polycomb Repressive Complex 1 | 1 | 2010 | 4 | 0.020 |
Why?
|
Polycomb-Group Proteins | 1 | 2010 | 9 | 0.020 |
Why?
|
Drug Therapy, Combination | 3 | 1983 | 893 | 0.020 |
Why?
|
Drug Administration Schedule | 3 | 1998 | 916 | 0.020 |
Why?
|
Documentation | 1 | 2011 | 98 | 0.020 |
Why?
|
Endoplasmic Reticulum | 1 | 1972 | 250 | 0.020 |
Why?
|
Ubiquitination | 1 | 2010 | 67 | 0.020 |
Why?
|
Mitoguazone | 1 | 1989 | 2 | 0.020 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2009 | 21 | 0.020 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2009 | 22 | 0.020 |
Why?
|
Point-of-Care Systems | 1 | 2011 | 141 | 0.020 |
Why?
|
Cellular Senescence | 1 | 2010 | 94 | 0.020 |
Why?
|
Vinblastine | 1 | 1989 | 108 | 0.020 |
Why?
|
Linear Models | 1 | 2011 | 419 | 0.020 |
Why?
|
Oxazoles | 1 | 1989 | 19 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2010 | 120 | 0.020 |
Why?
|
Drug Prescriptions | 1 | 2011 | 141 | 0.020 |
Why?
|
Lysine | 1 | 2010 | 147 | 0.020 |
Why?
|
Coronary Disease | 1 | 2011 | 261 | 0.020 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2009 | 99 | 0.020 |
Why?
|
Aziridines | 2 | 1987 | 9 | 0.020 |
Why?
|
Program Evaluation | 1 | 2011 | 297 | 0.020 |
Why?
|
Myocardial Infarction | 1 | 2012 | 372 | 0.020 |
Why?
|
Isoxazoles | 1 | 1989 | 77 | 0.020 |
Why?
|
Leukopenia | 3 | 1985 | 65 | 0.020 |
Why?
|
Cadherins | 1 | 2009 | 151 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 1993 | 1562 | 0.020 |
Why?
|
Clinical Trials as Topic | 6 | 1987 | 1168 | 0.020 |
Why?
|
Length of Stay | 1 | 2012 | 697 | 0.020 |
Why?
|
Thyroid Neoplasms | 2 | 1986 | 406 | 0.020 |
Why?
|
Kidney Neoplasms | 2 | 1985 | 620 | 0.020 |
Why?
|
Edible Grain | 1 | 2007 | 9 | 0.020 |
Why?
|
Vegetables | 1 | 2007 | 45 | 0.020 |
Why?
|
Fluorouracil | 3 | 1992 | 556 | 0.020 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2007 | 45 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2011 | 1015 | 0.020 |
Why?
|
Protein Processing, Post-Translational | 1 | 2009 | 371 | 0.020 |
Why?
|
Fruit | 1 | 2007 | 75 | 0.020 |
Why?
|
Acid Phosphatase | 2 | 1985 | 33 | 0.020 |
Why?
|
Carcinoma, Endometrioid | 1 | 2007 | 43 | 0.020 |
Why?
|
Astrocytoma | 1 | 1987 | 82 | 0.020 |
Why?
|
Liver | 1 | 1972 | 1229 | 0.020 |
Why?
|
Cohort Studies | 1 | 2013 | 2759 | 0.020 |
Why?
|
Chicago | 1 | 2011 | 1377 | 0.020 |
Why?
|
Deoxycytidine | 1 | 2007 | 237 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2010 | 662 | 0.020 |
Why?
|
Lung Neoplasms | 4 | 1995 | 2260 | 0.020 |
Why?
|
Medulloblastoma | 1 | 1986 | 36 | 0.020 |
Why?
|
Azirines | 1 | 1985 | 3 | 0.020 |
Why?
|
Quinazolines | 1 | 2007 | 220 | 0.020 |
Why?
|
Weight Loss | 1 | 2007 | 229 | 0.020 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2007 | 236 | 0.020 |
Why?
|
Radio Waves | 1 | 1985 | 17 | 0.020 |
Why?
|
Job Satisfaction | 1 | 2005 | 73 | 0.020 |
Why?
|
Germanium | 1 | 1984 | 4 | 0.020 |
Why?
|
Anthraquinones | 1 | 1984 | 8 | 0.020 |
Why?
|
Mitolactol | 1 | 1984 | 1 | 0.020 |
Why?
|
Spiro Compounds | 1 | 1984 | 25 | 0.020 |
Why?
|
Fatigue | 1 | 2005 | 174 | 0.020 |
Why?
|
Workload | 1 | 2005 | 128 | 0.020 |
Why?
|
Medical Errors | 1 | 2005 | 115 | 0.020 |
Why?
|
Hyperthermia, Induced | 1 | 1985 | 71 | 0.020 |
Why?
|
Sleep Deprivation | 1 | 2005 | 137 | 0.020 |
Why?
|
BCG Vaccine | 2 | 1984 | 31 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2009 | 1196 | 0.020 |
Why?
|
Thyroxine | 1 | 1986 | 344 | 0.020 |
Why?
|
Burnout, Professional | 1 | 2005 | 93 | 0.020 |
Why?
|
Interferon Type I | 1 | 1985 | 175 | 0.020 |
Why?
|
Organometallic Compounds | 1 | 1984 | 132 | 0.010 |
Why?
|
Apoptosis | 1 | 2010 | 1678 | 0.010 |
Why?
|
Young Adult | 1 | 2015 | 5961 | 0.010 |
Why?
|
Adjuvants, Immunologic | 1 | 1984 | 166 | 0.010 |
Why?
|
Mastectomy | 3 | 1980 | 234 | 0.010 |
Why?
|
Glioma | 1 | 1985 | 285 | 0.010 |
Why?
|
Indomethacin | 1 | 1983 | 59 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2011 | 801 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1983 | 274 | 0.010 |
Why?
|
Interferons | 1 | 1983 | 132 | 0.010 |
Why?
|
Regression Analysis | 1 | 2004 | 595 | 0.010 |
Why?
|
Carmustine | 2 | 1996 | 70 | 0.010 |
Why?
|
Radiotherapy | 2 | 1986 | 326 | 0.010 |
Why?
|
Attitude | 1 | 1983 | 126 | 0.010 |
Why?
|
Pheochromocytoma | 1 | 1982 | 49 | 0.010 |
Why?
|
Fibrosarcoma | 1 | 1982 | 84 | 0.010 |
Why?
|
Glucose Tolerance Test | 1 | 1982 | 228 | 0.010 |
Why?
|
Depression | 1 | 2005 | 472 | 0.010 |
Why?
|
Energy Intake | 2 | 1993 | 97 | 0.010 |
Why?
|
Adrenal Gland Neoplasms | 1 | 1982 | 80 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2012 | 2183 | 0.010 |
Why?
|
Monocytes | 1 | 1983 | 214 | 0.010 |
Why?
|
Syndrome | 1 | 1982 | 446 | 0.010 |
Why?
|
Heart Failure | 1 | 2011 | 1196 | 0.010 |
Why?
|
Mastectomy, Segmental | 1 | 2001 | 91 | 0.010 |
Why?
|
Random Allocation | 3 | 1986 | 332 | 0.010 |
Why?
|
Pleural Neoplasms | 1 | 1982 | 188 | 0.010 |
Why?
|
Rodentia | 1 | 1980 | 42 | 0.010 |
Why?
|
Drug Evaluation, Preclinical | 1 | 1980 | 103 | 0.010 |
Why?
|
Lymphedema | 1 | 2001 | 77 | 0.010 |
Why?
|
Streptozocin | 1 | 1979 | 54 | 0.010 |
Why?
|
Remission, Spontaneous | 1 | 1979 | 53 | 0.010 |
Why?
|
Cyanides | 1 | 1979 | 16 | 0.010 |
Why?
|
Drug Tolerance | 1 | 1979 | 63 | 0.010 |
Why?
|
Rats | 2 | 1979 | 3984 | 0.010 |
Why?
|
Sodium Chloride | 1 | 1979 | 86 | 0.010 |
Why?
|
Infusions, Intravenous | 2 | 1989 | 429 | 0.010 |
Why?
|
Gastrointestinal Neoplasms | 1 | 1979 | 106 | 0.010 |
Why?
|
DNA Primers | 1 | 1999 | 542 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2004 | 1610 | 0.010 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 1998 | 165 | 0.010 |
Why?
|
Doxorubicin | 2 | 1992 | 289 | 0.010 |
Why?
|
Transplantation, Autologous | 1 | 1979 | 328 | 0.010 |
Why?
|
Adolescent | 4 | 1987 | 8968 | 0.010 |
Why?
|
Physicians | 1 | 2005 | 672 | 0.010 |
Why?
|
Skin | 1 | 2001 | 554 | 0.010 |
Why?
|
Bone Marrow | 1 | 1979 | 434 | 0.010 |
Why?
|
Quality of Life | 1 | 2005 | 1575 | 0.010 |
Why?
|
Chlorambucil | 1 | 1977 | 23 | 0.010 |
Why?
|
Bone Neoplasms | 3 | 1985 | 322 | 0.010 |
Why?
|
Long-Term Care | 1 | 1977 | 60 | 0.010 |
Why?
|
Mitomycin | 1 | 1996 | 29 | 0.010 |
Why?
|
Karnofsky Performance Status | 1 | 1996 | 40 | 0.010 |
Why?
|
Mercaptopurine | 1 | 1996 | 53 | 0.010 |
Why?
|
Cell Line | 1 | 1999 | 2466 | 0.010 |
Why?
|
Quality Assurance, Health Care | 1 | 1996 | 220 | 0.010 |
Why?
|
Vitamins | 1 | 1993 | 81 | 0.010 |
Why?
|
Receptors, Estrogen | 2 | 1984 | 382 | 0.010 |
Why?
|
Benz(a)Anthracenes | 1 | 1972 | 4 | 0.010 |
Why?
|
Melphalan | 2 | 1984 | 97 | 0.010 |
Why?
|
Paralysis | 1 | 1972 | 23 | 0.010 |
Why?
|
Sarcoma, Experimental | 1 | 1972 | 53 | 0.010 |
Why?
|
Body Weight | 1 | 1993 | 459 | 0.010 |
Why?
|
Organophosphate Poisoning | 1 | 1971 | 2 | 0.010 |
Why?
|
Poisoning | 1 | 1971 | 42 | 0.010 |
Why?
|
Feasibility Studies | 1 | 1993 | 751 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 1972 | 502 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 1972 | 391 | 0.010 |
Why?
|
Organ Size | 1 | 1972 | 363 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 1990 | 156 | 0.010 |
Why?
|
Postoperative Care | 2 | 1980 | 220 | 0.010 |
Why?
|
Electrocardiography | 1 | 1971 | 478 | 0.010 |
Why?
|
Dacarbazine | 1 | 1987 | 102 | 0.000 |
Why?
|
Vincristine | 1 | 1986 | 111 | 0.000 |
Why?
|
Statistics as Topic | 1 | 1987 | 237 | 0.000 |
Why?
|
Cyclohexenes | 1 | 1985 | 5 | 0.000 |
Why?
|
Gastrointestinal Diseases | 1 | 1987 | 145 | 0.000 |
Why?
|
Castration | 1 | 1985 | 38 | 0.000 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 1989 | 850 | 0.000 |
Why?
|
Thermal Conductivity | 1 | 1985 | 3 | 0.000 |
Why?
|
Multi-Institutional Systems | 1 | 1985 | 4 | 0.000 |
Why?
|
Stomach Ulcer | 1 | 1985 | 23 | 0.000 |
Why?
|
Child | 2 | 1987 | 6913 | 0.000 |
Why?
|
Body Temperature | 1 | 1985 | 124 | 0.000 |
Why?
|
Leukocyte Count | 1 | 1985 | 220 | 0.000 |
Why?
|
Mitoxantrone | 1 | 1984 | 68 | 0.000 |
Why?
|
Prednisolone | 1 | 1984 | 41 | 0.000 |
Why?
|
Anemia | 1 | 1985 | 128 | 0.000 |
Why?
|
Nausea | 1 | 1985 | 175 | 0.000 |
Why?
|
Pain Management | 1 | 1985 | 126 | 0.000 |
Why?
|
Vomiting | 1 | 1985 | 193 | 0.000 |
Why?
|
Pulmonary Fibrosis | 1 | 1985 | 123 | 0.000 |
Why?
|
Burns | 1 | 1985 | 129 | 0.000 |
Why?
|
Radiography | 1 | 1985 | 812 | 0.000 |
Why?
|
Phytohemagglutinins | 1 | 1983 | 22 | 0.000 |
Why?
|
Pain | 1 | 1985 | 389 | 0.000 |
Why?
|
Cell Adhesion | 1 | 1983 | 418 | 0.000 |
Why?
|
Cell Division | 1 | 1983 | 696 | 0.000 |
Why?
|
Lymphocytes | 1 | 1983 | 461 | 0.000 |
Why?
|
Maxillary Neoplasms | 1 | 1980 | 6 | 0.000 |
Why?
|
Hematuria | 1 | 1980 | 49 | 0.000 |
Why?
|
Child, Preschool | 1 | 1986 | 3608 | 0.000 |
Why?
|
Thymus Gland | 1 | 1979 | 195 | 0.000 |
Why?
|
Preoperative Care | 1 | 1980 | 390 | 0.000 |
Why?
|
Immunotherapy | 1 | 1983 | 627 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 1986 | 2594 | 0.000 |
Why?
|